About this trial

Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception, including individual variation in symptoms, severity, and treatment response. This heterogeneity complicates understanding of depression and thwarts progress toward disease classification and treatment planning. Discovery of depression-specific biomarkers that account for neurobiological variation that presumably underlies distinct clinical manifestations is critical to this larger effort.

Eligibility criteria

Qualifiers

Our studies require some in-person visits to our research lab, located at 42nd Ave and Clement St in San Francisco.

Because this study includes an MRI, part of the screening process will be to ensure you don't have any metal in your body, you do not have head or neck tattoos, and you are comfortable inside the MRI scanner.

18-70 years with a diagnosis of major depressive disorder (MDD) for MDD group, or without for unaffected comparison (UC) group

Negative metal screen for MRI safety

Disqualifiers

Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive symptoms)

Loss of consciousness (LOC) greater than 30 minutes or any LOC with neurologic symptoms

Major medical conditions (e.g., seizure disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology)

Substance dependence, within the past year, or failed urine toxicology on the day of neuroimaging sessions

Trial design

Treatments tested in this trial

  • cross-sectional MRI and EEG assessments (NO INTERVENTION)

Treatment groups

150 Participants
are divided into 2 treatment groups

Locations

1
San Francisco Healthcare System94121, San FranciscoCalifornia, United States

Sponsors and collaborators

San Francisco Veterans Affairs Medical Center

Lead sponsor